143 related articles for article (PubMed ID: 28472235)
1. Clinical validation of a prognostic tool in a population of outpatients treated for incurable cancer undergoing anticancer therapy: PRONOPALL study.
Bourgeois H; Grudé F; Solal-Céligny P; Dupuis O; Voog E; Ganem G; Denis F; Zinger M; Juhel-Voog L; Lafond C; Maillart P; Capitain O; Delva R; Soulié P; Abadie-Lacourtoisie S; Guérin-Meyer V; Morin-Meschin ME; Commer JM; Gangler A; d'Aillières B; Zannetti A; Bourbouloux E; Berton-Rigault D; Lebouvier-Sadot S; Kaassis M; Baudon J; Lam YH; Bizieux A; Marcq M; Edeline J; Le Du F; Lefeuvre C; Deguiral P; Delecroix V; Blot E; Egreteau J; Goudier MJ; Lamy R; Ferec M; Artignan X; Corbinais S; Morel H; Hardy-Bessard AC; Alleaume C; Naudeix E; Cojocarasu O; Metges JP; Riché C; Gamelin E; Déniel-Lagadec D; Marhuenda F; Ingrand P; Douillard JY
Ann Oncol; 2017 Jul; 28(7):1612-1617. PubMed ID: 28472235
[TBL] [Abstract][Full Text] [Related]
2. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).
Bigot F; Castanon E; Baldini C; Hollebecque A; Carmona A; Postel-Vinay S; Angevin E; Armand JP; Ribrag V; Aspeslagh S; Varga A; Bahleda R; Menis J; Gazzah A; Michot JM; Marabelle A; Soria JC; Massard C
Eur J Cancer; 2017 Oct; 84():212-218. PubMed ID: 28826074
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.
Gravis G; Boher JM; Fizazi K; Joly F; Priou F; Marino P; Latorzeff I; Delva R; Krakowski I; Laguerre B; Walz J; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M; Oudard S
Eur Urol; 2015 Aug; 68(2):196-204. PubMed ID: 25277272
[TBL] [Abstract][Full Text] [Related]
4. Overall survival of cancer patients with serum lactate dehydrogenase greater than 1000 IU/L.
Liu R; Cao J; Gao X; Zhang J; Wang L; Wang B; Guo L; Hu X; Wang Z
Tumour Biol; 2016 Oct; 37(10):14083-14088. PubMed ID: 27511116
[TBL] [Abstract][Full Text] [Related]
5. Analysis of prognostic factors and applicability of Kohne's prognostic groups in patients with metastatic colorectal cancer treated with first-line irinotecan or oxaliplatin-based chemotherapy.
Díaz R; Aparicio J; Gironés R; Molina J; Palomar L; Segura A; Montalar J
Clin Colorectal Cancer; 2005 Sep; 5(3):197-202. PubMed ID: 16197623
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of modified Glasgow prognostic score in recurrent high-grade glial tumors treated with systemic treatment.
Alan O; Telli TA; Basoğlu T; Arikan R; Demircan NC; Ercelep O; Bozkurt S; Atasoy BM; Dane F; Yumuk PF
Clin Neurol Neurosurg; 2020 Sep; 196():105976. PubMed ID: 32531614
[TBL] [Abstract][Full Text] [Related]
7. Prognostic scores for sorafenib-treated hepatocellular carcinoma patients: A new application for the hepatoma arterial embolisation prognostic score.
Edeline J; Blanc JF; Campillo-Gimenez B; Ma YT; King J; Faluyi O; Mathurin J; Ghazi S; Palmer DH; Meyer T
Eur J Cancer; 2017 Nov; 86():135-142. PubMed ID: 28987770
[TBL] [Abstract][Full Text] [Related]
8. Inpatient palliative chemotherapy is associated with high mortality and aggressive end-of-life care in patients with advanced solid tumors and poor performance status.
Fiorin de Vasconcellos V; Rcc Bonadio R; Avanço G; Negrão MV; Pimenta Riechelmann R
BMC Palliat Care; 2019 May; 18(1):42. PubMed ID: 31109330
[TBL] [Abstract][Full Text] [Related]
9. Prospective validation of a prognostic score to improve patient selection for oncology phase I trials.
Arkenau HT; Barriuso J; Olmos D; Ang JE; de Bono J; Judson I; Kaye S
J Clin Oncol; 2009 Jun; 27(16):2692-6. PubMed ID: 19332724
[TBL] [Abstract][Full Text] [Related]
10. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
11. Palliative care in poor-performance status small cell lung cancer patients: is there a mandatory role for chemotherapy?
Baldotto CS; Cronemberger EH; de Biasi P; Zamboni M; Sousa A; Zukin M; Small IA; Ferreira CG
Support Care Cancer; 2012 Nov; 20(11):2721-7. PubMed ID: 22322592
[TBL] [Abstract][Full Text] [Related]
12. A laboratory prognostic index model for patients with advanced non-small cell lung cancer.
Ulas A; Turkoz FP; Silay K; Tokluoglu S; Avci N; Oksuzoglu B; Alkis N
PLoS One; 2014; 9(12):e114471. PubMed ID: 25474743
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Hematologic and Other Prognostic Markers in Metastatic Colorectal Cancer.
Mercier J; Voutsadakis IA
J Gastrointest Cancer; 2019 Sep; 50(3):493-506. PubMed ID: 29704170
[TBL] [Abstract][Full Text] [Related]
14. Prognostic significance of C-reactive protein and smoking in patients with advanced non-small cell lung cancer treated with first-line palliative chemotherapy.
Koch A; Fohlin H; Sörenson S
J Thorac Oncol; 2009 Mar; 4(3):326-32. PubMed ID: 19155996
[TBL] [Abstract][Full Text] [Related]
15. Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small-cell lung cancer patients treated with first-line platinum-containing chemotherapy.
He M; Chi X; Shi X; Sun Y; Yang X; Wang L; Wang B; Li H
Thorac Cancer; 2021 Dec; 12(23):3101-3109. PubMed ID: 34725930
[TBL] [Abstract][Full Text] [Related]
16. Palliative chemotherapy for gastroesophageal cancer in old and very old patients: A retrospective cohort study at the National Center for Tumor Diseases, Heidelberg.
Berger AK; Zschaebitz S; Komander C; Jäger D; Haag GM
World J Gastroenterol; 2015 Apr; 21(16):4911-8. PubMed ID: 25945004
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of Baseline ALBI Score Among Patients With Colorectal Liver Metastases: A Pooled Analysis of Two Randomized Trials.
Abdel-Rahman O
Clin Colorectal Cancer; 2019 Mar; 18(1):e61-e68. PubMed ID: 30348618
[TBL] [Abstract][Full Text] [Related]
18. Simplified prognostic model in patients with oxaliplatin-based or irinotecan-based first-line chemotherapy for metastatic colorectal cancer: a GERCOR study.
Chibaudel B; Bonnetain F; Tournigand C; Bengrine-Lefevre L; Teixeira L; Artru P; Desramé J; Larsen AK; André T; Louvet C; de Gramont A
Oncologist; 2011; 16(9):1228-38. PubMed ID: 21859820
[TBL] [Abstract][Full Text] [Related]
19. "How Long Have I Got?"-A Prospective Cohort Study Comparing Validated Prognostic Factors for Use in Patients with Advanced Cancer.
Simmons C; McMillan DC; Tuck S; Graham C; McKeown A; Bennett M; O'Neill C; Wilcock A; Usborne C; Fearon KC; Fallon M; Laird BJ;
Oncologist; 2019 Sep; 24(9):e960-e967. PubMed ID: 30975922
[TBL] [Abstract][Full Text] [Related]
20. Prognostic score for patients with advanced melanoma treated with ipilimumab.
Diem S; Kasenda B; Martin-Liberal J; Lee A; Chauhan D; Gore M; Larkin J
Eur J Cancer; 2015 Dec; 51(18):2785-91. PubMed ID: 26597444
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
